Literature DB >> 7596624

The hypoalgesic effect of imipramine in different human experimental pain models.

L Poulsen1, L Arendt-Nielsen, K Brøsen, K K Nielsen, L F Gram, S H Sindrup.   

Abstract

In a randomized, placebo-controlled, double-blind, cross-over study, the hypoalgesic effect of a single oral dose of 100 mg imipramine was investigated in 12 healthy volunteers. Test procedures performed before, 3, 6, and 9 h after medication included determination of (1) pain detection and tolerance thresholds to heat and pressure; (2) the thresholds of quadriceps femoris muscle withdrawal reflex to single and repeated electric stimulation of the sural nerve; (3) amplitude of the reflex evoked by 1.5 times the premedication reflex threshold; and (4) continuous pain rating during the cold pressor test. Imipramine significantly increased pain tolerance thresholds to heat (P = 0.03) and pressure (P = 0.01), and both the psychophysical pain tolerance threshold and the reflex threshold to single electric stimulation (P = 0.02 and P = 0.03, respectively). On the repeated stimuli, which consisted of 4 pulses given at 3 Hz, imipramine induced a significant increase in the threshold at which the pain summated through the stimulation series (P = 0.03), whereas the increase in the threshold at which the reflex summated was not significant (P = 0.09). Pain detection thresholds to heat and pressure, the amplitude of the reflex to single suprathreshold stimulation, and pain ratings during the cold pressor test were unaltered by imipramine. It is concluded that imipramine has a differential hypoalgesic effect on different human experimental pain tests. This provides new possibilities of assessing the differential effect of different tricyclic antidepressants on different pain modalities and intensities.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7596624     DOI: 10.1016/0304-3959(94)00142-2

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  15 in total

Review 1.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 2.  Pharmacological management of neuropathic pain.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Antidepressants as analgesics.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs.

Authors:  A Truini; G Panuccio; F Galeotti; M R Maluccio; F Sartucci; M Avoli; G Cruccu
Journal:  Eur J Pain       Date:  2009-05-23       Impact factor: 3.931

5.  Gender differences in pain and biomechanical responses after acid sensitization of the human esophagus.

Authors:  Hariprasad Reddy; Lars Arendt-Nielsen; Camilla Staahl; Jan Pedersen; Peter Funch-Jensen; Hans Gregersen; Asbjørn Mohr Drewes
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 6.  How do drugs relieve neurogenic pain?

Authors:  R Karlsten; T Gordh
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 3.923

Review 7.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

8.  Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients.

Authors:  C Prakash; P J Lustman; K E Freedland; R E Clouse
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

Review 9.  Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers: an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

10.  Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans.

Authors:  Eva Kosek; Karin B Jensen; Tina B Lonsdorf; Martin Schalling; Martin Ingvar
Journal:  Mol Pain       Date:  2009-07-01       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.